Eli Lilly to sign $2 billion deal for AI drug development with Hong Kong's Insilico Medicine, FT says

Insilico Medicine Cayman TopCo

29/03/2026 12:13

March 29 (Reuters) - Eli Lilly LLY.N will sign a $2 billion deal with Hong Kong-listed biotech Insilico Medicine 3696.HK, which uses artificial intelligence for drug discovery, the Financial Times reported on Sunday.

Lilly will acquire exclusive rights to sell a GLP-1 drug for diabetes from Insilico Medicine, the FT report said, citing sources familiar with the matter.

Reuters could not immediately verify the report.

 (Reporting by Rishabh Jaiswal in Bengaluru. Editing by Mark Potter)

 ((rishabh.jaiswal@thomsonreuters.com; +91 9916719147))